Reduction of BRCA1 expression in sporadic ovarian cancer

Gynecologic Oncology

Volumn 76, Issue 3, 2000, Pages 294-300

  Zheng, Wenxin ^a   Luo, Feng ^a   Lu, Jean J ^a   Baltayan, Armine ^a   Press, Michael F ^a   Zhang, Zuo Feng ^b   Pike, Malcolm C ^a  

^a UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

BRCA1; Cell proliferation; Ovarian cancer

Indexed keywords

BRCA1 PROTEIN; KI 67 ANTIGEN;

ARTICLE; CANCER GRADING; CELL PROLIFERATION; CYSTADENOMA; FAMILIAL CANCER; FEMALE; GENE MUTATION; HUMAN; HUMAN CELL; HUMAN TISSUE; MAJOR CLINICAL STUDY; OVARY CARCINOMA; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION;

EID: 0034107710     PISSN: 00908258     EISSN: None     Source Type: Journal    
DOI: 10.1006/gyno.1999.5664     Document Type: Article

References (36)

1. Miki Y, Swensen J, Shattuck-Eidens D, Futreal P, Harshman K, Tavtigian S, Liu Q, Cochran C, Bennett L M, Ding W, Bell R, Rosenthal J, Hussey C, Tran T, McClure M, Frye C, Hattier T, Phelps R, Haugen-Strano A, Katcher H, Yakumo K, Gholami Z, Shaffer D, Stone S, Bayer S, Wray C, Borgden R, Dayananth P, Ward J, Tonin P, Narod S, Bristow P, Norris F, Helvering L, Morrison P, Roseteck P, Lai M, Barrett J C, Lewis C, Neuhausen S, Cannon-Albright L, Goldgar D, Wiseman R, Kamb A, Skolnick M H. A strong candidate for the breast and ovarian cancer susceptibility gene BRCA1. Science. 266:1994;66-71.
2. Boyd J. Molecular genetics of hereditary ovarian cancer. Oncology (Huntingt). 12:1998;399-406.
3. Thompson M E, Jensen R A, Obermiller P S, Page D L, Holt J T. Decreased expression of BRCA1 accelerates growth and is often present during sporadic breast cancer progression. Nat Genet. 9:1995;444-450.
4. Holt J T, Thompson M E, Szabo C, Robinson-Benion C, Arteaga C L, King M C, Jensen R A. Growth retardation and tumour inhibition by BRCA1. Nat Genet. 12:1996;298-302.
5. Jarvis E M, Kirk J A, Clarke C L. Loss of nuclear BRCA1 expression in breast cancers is associated with a highly proliferative tumor phenotype. Cancer Genet Cytogenet. 101:1998;109-115.
6. Magdinier F, Ribieras S, Lenoir G M, Frappart L, Dante R. Down-regulation of BRCA1 in human sporadic breast cancer, analysis of DNA methylation patterns of the putative promoter region. Oncogene. 17:1998;3169-3176.
7. Sourvinos G, Spandidos D A. Decreased BRCA1 expression levels may arrest the cell cycle through activation of p53 checkpoint in human sporadic breast tumors. Biochem Biophys Res Commun. 245:1998;75-80.
8. Wilson C A, Ramos L, Villasenor R, Anders K, Press M F, Clarke K, Karlan B, Chen J J, Scully R, Livingston D, Zuch R H, Kanter M H, Cohen S, Calzone F J, Slamon D J. Localization of human BRCA1 and its loss in high-grade, non-inherited breast carcinomas. Nat Genet. 21:1999;236-240.
9. Marquis S T, Rajan J V, Wynshaw-Boris A, Xu J, Yin G Y, Abel K J, Weber B L, Chodosh L A. The developmental pattern of Brca1 expression implies a role in differentiation of the breast and other tissues. Nat Genet. 11:1995;17-26.
10. Gudas J M, Li T, Nguyen H, Jensen D, Rauscher F Jr, Cowan K H. Cell cycle regulation of BRCA1 messenger RNA in human breast epithelial cells. Cell Growth Different. 7:1996;717-723.
11. Cattoretti G, Becker M H, Key G, Duchrow M, Schluter C, Galle J, Gerdes J. Monoclonal antibodies against recombinant parts of the Ki-67 antigen (MIB 1 and MIB 3) detect proliferating cells in microwave-processed formalin-fixed paraffin sections. J Pathol. 168:1992;357-363.
12. Zheng W, Luo M P, Welt C, Lambert-Messerlian G, Sung C J, Schneyer A, Lauchlan S C, Felix J C. Imbalanced expression of inhibin and activin subunits in primary epithelial ovarian cancer. Gynecol Oncol. 69:1998;23-31.
13. Phillips K W, Goldsworthy S M, Bennett L M, Brownlee H A, Wiseman R W, Davis B J. BRCA1 is expressed independently of hormonal stimulation in the mouse ovary. Lab Invest. 76:1997;419-425.
14. Key G, Petersen J L, Becker M H, Duchrow M, Schluter C, Askaa J, Gerdes J. New antiserum against Ki-67 antigen suitable for double immunostaining of paraffin wax sections. J Clin Pathol. 46:1993;1080-1084.
15. Darai E, Walker-Combrouze F, Dauge-Geoffroy M C, Vincent Y, Feldmann G, Madelenat P, Scoazec J Y. Ki 67 expression in 35 borderline ovarian tumours: relations with clinicopathologic parameters and ploidy. Eur J Obstet Gynecol Reprod Biol. 76:1998;175-180.
16. Sykes P J, Neoh S H, Brisco M J, Hughes E, Condon J, Morley A A. Quantitation of targets for PCR by use of limiting dilution. BioTechniques. 13:1992;444-449.
17. SAS/STAT User Guide, Version 6, Cary, NC, SAS Institute, Inc, 1990.
18. Hosking L, Trowsdale J, Nicolai H, Solomon E, Foulkes W, Stamp G, Signer E, Jeffreys A. A somatic BRCA1 mutation in an ovarian tumour. Nat Genet. 9:1995;343-344.
19. Merajver S D, Pham T M, Caduff R F, Chen M, Poy E L, Cooney K A, Weber B L, Collins F S, Johnston C, Frank T S. Somatic mutations in the BRCA1 gene in sporadic ovarian tumours. Nat Genet. 9:1995;439-443.
20. Fetzer S, Tworek H A, Piver M S, DiCioccio R A. Classification of IVS1-10T→C as a polymorphism of BRCA1. Cancer Genet Cytogenet. 113:1999;58-64.
21. Russell S E, Hickey G I, Lowry W S, White P, Atkinson R J. Allele loss from chromosome 17 in ovarian cancer. Oncogene. 5:1990;1581-1583.
22. Tangir J, Muto M G, Berkowitz R S, Welch W R, Bell D A, Mok S C. A 400 kb novel deletion unit centromeric to the BRCA1 gene in sporadic epithelial ovarian cancer. Oncogene. 12:1996;735-740.
23. Berchuck A, Heron K A, Carney M E, Lancaster J M, Fraser E G, Vinson V L, Deffenbaugh A M, Miron A, Marks J R, Futreal P A, Frank T S. Frequency of germline and somatic BRCA1 mutations in ovarian cancer. Clin Cancer Res. 4:1998;2433-2437.
24. Laird P W, Jaenisch R. The role of DNA methylation in cancer genetic and epigenetics. Ann Rev Genet. 30:1996;441-464.
25. Baylin S B, Herman J G, Graff J R, Vertino P M, Issa J P. Alterations in DNA methylation: a fundamental aspect of neoplasia. Adv Cancer Res. 72:1998;141-196.
26. Dobrovic A, Simpfendorfer D. Methylation of the BRCA1 gene in sporadic breast cancer. Cancer Res. 57:1997;3347-3350.
27. Rice J C, Massey-Brown K S, Futscher B W. Aberrant methylation of the BRCA1 CpG island promoter is associated with decreased BRCA1 mRNA in sporadic breast cancer cells. Oncogene. 17:1998;1807-1812.
28. Scully R, Chen J, Plug A, Xiao Y, Weaver D, Feunteun J, Ashley T, Livingston D M. Association of BRCA1 with Rad51 in mitotic and meiotic cells. Cell. 88:1997;265-275.
29. Scully R, Chen J, Ochs R L, Keegan K, Hoekstra M, Feunteun J, Livingston D M. Dynamic changes of BRCA1 subnuclear location and phosphorylation state are initiated by DNA damage. Cell. 90:1997;425-435.
30. Thomas J E, Smith M, Tonkinson J L, Rubinfeld B, Polakis P. Induction of phosphorylation of BRCA1 during the cell cycle and after DNA damage. Cell Growth Different. 8:1997;801-809.
31. Chen J, Silver D P, Walpita D, Cantor S B, Gazdar A F, Tomlinson G, Couch F J, Weber B L, Ashley T, Livingston D M, Scully R. Stable interaction between the products of the BRCA1 and BRCA2 tumor suppressor genes in mitotic and meiotic cells. Mol Cell. 2:1998;317-328.
32. Link C J, Reed E, Sarosy G, Kohn E C. Borderline ovarian tumors. Am J Med. 101:1996;217-225.
33. Silverberg S G. Prognostic significance of pathologic features of ovarian carcinoma. Curr Topic Pathol. 78:1989;85-109.
34. Isola J, Kallioniemi O P, Korte J M, Wahlstrom T, Aine R, Helle M, Helin H. Steroid receptors and Ki-67 reactivity in ovarian cancer and in normal ovary: correlation with DNA flow cytometry, biochemical receptor assay, and patient survival. J Pathol. 162:1990;295-301.
35. Pharoah P D, Easton D F, Stockton D L, Gayther S, Ponder B A. Survival in familial, BRCA1-associated, and BRCA2-associated epithelial ovarian cancer. Cancer Res. 59:1999;868-871.
36. Rubin S C, Benjamin I, Behbakht K, Takahashi H, Morgan M A, LiVolsi V A, Berchuck A, Muto M G, Garber J E, Weber B L, Lynch H T, Boyd J. Clinical and pathological features of ovarian cancer in women with germ-line mutations of BRCA1. N Engl J Med. 335:1996;1413-1416.